| Kidney Res Clin Pract > Volume 41(1); 2022 > Article |
|
Funding
This study was supported by the National Evidence Collaborating Agency (project number NECA-A-20-005). The funder had no role in performing the study, and the study was independently performed by the authors.
Authors’ contributions
Conceptualization: EK, SP, HL
Investigation: EK, YK, HJK, MH, JHC, JPL, SL, SWK, SMP, DWC, HJC, YSK, YCK, IC, HL
Formal analysis: EK, SP, JP, MP, KK
Funding acquisition: HL
Writing–original draft: EK, SP
Writing–review & editing: HL
All authors read and approved the final manuscript.
| Characteristic |
After matching |
||
|---|---|---|---|
| Donor (n = 1,701) | Control (n = 1,701) | p-value | |
| Matched variable | |||
| Agea (yr) | 44.0 (35.0–52.0) | 44.0 (36.0–52.0) | 0.64 |
| ≥60 | 107 (6.3) | 107 (6.3) | >0.99 |
| Sexa | >0.99 | ||
| Male | 792 (46.6) | 792 (46.6) | |
| Female | 909 (53.4) | 909 (53.4) | |
| Body mass index (kg/m2) | 23.4 (21.6–25.4) | 23.1 (21.0–25.4) | 0.002 |
| ≥25a | 512 (30.1) | 512 (30.1) | >0.99 |
| Underlying disease | |||
| Diabetes mellitusa | 46 (2.7) | 46 (2.7) | >0.99 |
| Hypertensiona | 283 (16.6) | 283 (16.6) | >0.99 |
| Creatinine (mg/dL) | 0.8 (0.7–0.9) | 0.8 (0.7–0.9) | 0.51 |
| eGFRa (mL/min/1.73 m2) | 100.3 (89.0–108.9) | 100.1 (89.1–108.5) | 0.46 |
| Dipstick albuminuriaa (≥1+) | 28 (1.6) | 28 (1.6) | >0.99 |
| Unmatched variable | |||
| Systolic blood pressure (mmHg) | 120.0 (110.0–130.0) | 118.0 (109.0–129.0) | 0.39 |
| Diastolic blood pressure (mmHg) | 73.0 (67.0–80.0) | 72.0 (65.0–79.0) | 0.002 |
| Hemoglobin (g/dL) | 13.7 (12.7–15.0) | 14.2 (13.1–15.4) | <0.001 |
| Uric acid (mg/dL) | 4.8 (4.0–5.9) | 5.1 (4.2–6.2) | <0.001 |
| Wealth percentile | <0.001 | ||
| 0 (aided) | 68 (4.0) | 2 (0.1) | |
| 1st–25th | 332 (19.5) | 174 (10.2) | |
| 26th–50th | 378 (22.2) | 198 (11.6) | |
| 51st–75th | 426 (25.0) | 369 (21.7) | |
| 76th–100th | 497 (29.2) | 958 (56.3) | |
| Place of residence | <0.001 | ||
| Rural | 588 (34.6) | 269 (15.8) | |
| Urban | 1,113 (65.4) | 1,432 (84.2) | |
| Matching and group | Outcome/subjects (n) |
Univariable model |
Age-sex adjusted model | Multivariable modela | |||
|---|---|---|---|---|---|---|---|
| HR (95% CI) | p-value | Adjusted HR (95% CI) | p-value | Adjusted HR (95% CI) | p-value | ||
| Before matching | |||||||
| Donor | 24/1,751 | 0.60 (0.40–0.90) | 0.01 | 1.68 (1.12–2.52) | 0.01 | 1.41 (0.94–2.13) | 0.10 |
| Control | 2,533/71,903 | Reference | Reference | Reference | |||
| After matching | |||||||
| Donor | 24/1,701 | 2.01 (1.01–4.03) | 0.05 | 2.00 (1.00–4.00) | 0.05 | 1.82 (0.87–3.80) | 0.11 |
| Control | 12/1,701 | Reference | Reference | ||||
| Variable | No. of donors | Event |
Univariable model |
Multivariable modela |
||
|---|---|---|---|---|---|---|
| HR (95% CI) | p-value | Adjusted HR (95% CI) | p-value | |||
| Age (yr) | ||||||
| <60 | 1,644 | 19 | Reference | |||
| ≥60 | 107 | 5 | 6.05 (2.23–16.36) | <0.001 | 6.50 (2.39–17.68) | <0.001 |
| Sex | ||||||
| Male | 829 | 12 | Reference | |||
| Female | 922 | 12 | 0.96 (0.43–2.14) | 0.92 | ||
| Body mass index (kg/m2) | ||||||
| <25 | 1,220 | 18 | Reference | |||
| ≥25 | 531 | 6 | 0.85 (0.34–2.13) | 0.72 | ||
| eGFR (mL/min/1.73 m2) | ||||||
| <80 | 174 | 4 | Reference | |||
| ≥80 | 1,577 | 20 | 0.74 (0.25–2.18) | 0.59 | ||
| Dipstick albuminuria | ||||||
| Trace or – | 1,722 | 24 | Reference | |||
| ≥1+ | 29 | 0 | NA | |||
| Diabetes mellitus | ||||||
| No | 1,702 | 24 | Reference | |||
| Yes | 49 | 0 | NA | |||
| Hypertension | ||||||
| No | 1,458 | 20 | Reference | |||
| Yes | 293 | 4 | 1.09 (0.37–3.19) | 0.88 | ||
| Wealth percentile | ||||||
| 0 (aided) | 68 | 1 | Reference | |||
| 1st–25th | 346 | 5 | 1.33 (0.16–11.43) | 0.79 | ||
| 26th–50th | 390 | 6 | 1.38 (0.17–11.46) | 0.77 | ||
| 51st–75th | 438 | 5 | 1.00 (0.12–8.55) | >0.99 | ||
| 76th–100th | 509 | 7 | 1.19 (0.15–9.66) | 0.87 | ||
| Place of residence | 24 | |||||
| Rural | 610 | 9 | Reference | |||
| Urban | 1,141 | 15 | 0.91 (0.40–2.08) | 0.82 | ||
| Relation | ||||||
| Parent-sibling | 669 | 10 | Reference | |||
| Brothers, sisters, or other relatives | 546 | 9 | 0.86 (0.35–2.11) | 0.74 | ||
| Unrelated | 533 | 5 | 0.64 (0.22–1.86) | 0.41 | ||
| Operation method | ||||||
| Laparoscopy | 1,232 | 17 | Reference | |||
| Open | 320 | 4 | 0.40 (0.13–1.27) | 0.12 | ||
| Donated kidney side | ||||||
| Left | 1,616 | 21 | Reference | |||
| Right | 131 | 2 | 0.93 (0.22–3.99) | 0.93 | ||
The effect sizes in the multivariable model were different from those in the univariable model, although a single variable (age ≥ 60 years) remained after backward elimination because the multivariable analysis was performed with 1,744 individuals due to missing data for the considered variables.
CI, confidence interval; eGFR, estimated glomerular filtration rate; HR, hazard ratio; NA, not applicable.
| Variable | Current study | Mjøen et al. [1] (2014) | Muzaale et al. [6] (2014) | Segev et al. [2] (2010) | Kim et al. [4] (2020) |
|---|---|---|---|---|---|
| No. of donors | 1,701 | 1,901 | 96,217 | 80,347 | 1,292 |
| Control | Subjects who received general health screenings voluntarily | HUNT 1 including BP ≤ 140/90 mmHg, BMI ≤ 30 kg/m2, and those who rated their own health as ‘good’ or ‘excellent’ | NHANES III after excluding those with contraindications to kidney donation | NHANES III after excluding those with contraindications to kidney donation | Subjects who received general health screenings voluntarily |
| Age (yr) | Median: 44.0 (35–51) | Mean: 46.0 ± 11.5 | 40.2 ± 11.1 | 18–39 (49.2%) | 40.7 ± 11.1 |
| 40–49 (30.3%) | |||||
| 50–59 (16.7%) | |||||
| ≥60 (3.8%) | |||||
| Male sex | 46.6% | 41% | 41% | 41.5% | 47.7% |
| Race | Asian (100%) | NA | White (74.6%) | White (73.1%) | Asian (100%) |
| Black (12.9%) | Black (13.1%) | ||||
| Hispanic (12.5%) | Hispanic (12.3%) | ||||
| Others (1.6%) | |||||
| eGFR (mL/min/1.73 m2) | Median: 100.3 | Mean: 104.7 | Means: 100.7 (donor), 86.4 (control) | 117 mL/min (creatinine clearance) | Mean: 96.0 |
| BMI (kg/m2) | Median: | Mean: 24.2 ± 2.8 | Mean: 26.7 ± 7.5 | 15–24 (37.0%) | Mean: 23.5 ± 3.0 |
| 23.4 (21.6–25.4) | 25–29 (40.4%) | ||||
| ≥ 30 (22.6%) | |||||
| History of DM | 2.7%/2.7% | NA, excluded from controls | NA, excluded from controls | NA, excluded from controls | NA, excluded from controls |
| History of HTN | 16.6%/16.6% | 0%, excluded from controls | NA, matching with SBP | 1.8%, excluded from controls | NA, excluded from controls |
| Systolic blood pressure (mmHg) | Median: 120 (110–130) | Mean: 123.3 ± 10.0 | Mean: 121.0 ± 16.3 | <120 (53.3%) | Mean: 116.6 ± 12.0 |
| 120–139 (39.6%) | |||||
| ≥140 (7.1) | |||||
| Matching variable | Age, sex, BMI, DM, HTN, eGFR, albuminuria, era | Age, sex, BP, smoking status | Age, sex, race, BP, educational background, BMI, smoking status | Age, sex, race/ethnicity, educational background, smoking status, BMI, SBP | Age, sex, BMI, eGFR, albuminuria, HTN, DM, era |
| All-cause mortality incidence proportion (n), in donors/in controls | 1.4% (24)/0.7% (12) | 11.8% (224)/7.4% (2,425) | NA | 3.1 per 10,000 donors/0.4 per 10,000 controls within 3 mo | 4.0% (52)/3.2% (1,072) |
| 6.5 per 10,000 donors/4.6 per 10,000 controls within 12 mo | |||||
| ESKD incidence proportion (n), in donors/in controls | 0% (0)/0% (0) | 0.47% (9)/0.06% (22) | 0.10% (99)/0.04% (36) | NA | NA |
| Follow-up (yr) | Median: 7.65 (4.15–11.13) | Median: 15.1 (1.5–43.9) | Median: 7.6 (maximum: 15.0) | Median: 6.3 (3.2–9.8) | Mean: 12.3 ± 8.1 |
BMI, body mass index; BP, blood pressure; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; ESKD, end-stage kidney disease; HTN, hypertension; HUNT, Health Study of Nord-Trøndelag; NA, not applicable; NHANES III, the third National Health and Nutritional Examination Survey; SBP, systolic BP.
Eunjeong Kang
https://orcid.org/0000-0002-2191-2784
Sehoon Park
https://orcid.org/0000-0002-4221-2453
Jina Park
https://orcid.org/0000-0002-7410-1985
Yaerim Kim
https://orcid.org/0000-0003-1596-1528
Minsu Park
https://orcid.org/0000-0002-0624-5215
Kwangsoo Kim
https://orcid.org/0000-0002-4586-5062
Hyo Jeong Kim
https://orcid.org/0000-0002-5618-0042
Miyeun Han
https://orcid.org/0000-0001-7304-2496
Jang-Hee Cho
https://orcid.org/0000-0002-7031-5214
Jung Pyo Lee
https://orcid.org/0000-0002-4714-1260
Sik Lee
https://orcid.org/0000-0002-9043-8166
Soo Wan Kim
https://orcid.org/0000-0002-3540-9004
Sang Min Park
https://orcid.org/0000-0002-7498-4829
Dong-Wan Chae
https://orcid.org/0000-0001-9401-892X
Ho Jun Chin
https://orcid.org/0000-0003-1185-2631
Yong Chul Kim
https://orcid.org/0000-0003-3215-8681
Yon Su Kim
https://orcid.org/0000-0003-3091-2388
Insun Choi
https://orcid.org/0000-0003-2091-5964
Hajeong Lee
https://orcid.org/0000-0002-1873-1587
Tegoprazan and the risk of end-stage kidney disease progression: a nationwide Korean study
Revisiting the safety of hypertensive kidney donors: a call for vigilance2025 July;44(4)
